```html

Klinenberg Disease (Hypocalcemia)

Overview

Klinenberg disease is the historical eponym used for a rare hereditary form of severe hypocalcemia that was first described by Dr. Robert Klinenberg in the early 1970s. In contemporary medical literature the condition is classified under the broader umbrella of hypocalcemia—a state of low calcium levels in the blood—often linked to specific genetic mutations that impair parathyroid hormone (PTH) secretion or action.

While hypocalcemia itself is relatively common (affecting up to 1‑2 % of the general adult population during hospital stays)¹, the genetic variant known as Klinenberg disease accounts for a tiny fraction—estimated at less than 1 in 100,000 individuals worldwide. It can present at any age but is most often diagnosed in childhood or early adulthood when calcium‑related symptoms become apparent.

Symptoms

Symptoms arise because calcium is essential for nerve transmission, muscle contraction, and bone health. The severity of clinical manifestations correlates with how low the serum calcium concentration falls (normal: 8.5–10.5 mg/dL).

Neuromuscular symptoms

• Paraesthesia – tingling or “pins‑and‑needles” sensations, most commonly around the mouth, fingers, and toes.
• Muscle cramps & spasms – sudden, painful involuntary contractions, especially in the calves (Calcium tetany).
• Positive Chvostek sign – facial muscle twitch when the facial nerve is tapped.
• Positive Trousseau sign – carpopedal spasm after inflating a blood pressure cuff for 3 minutes.
• Seizures – generalized or focal seizures can occur in severe, untreated cases.

Cardiovascular symptoms

• Prolonged QT interval on ECG, which may lead to arrhythmias.
• Palpitations or fainting (syncope) due to low calcium‑induced conduction abnormalities.

Gastrointestinal symptoms

• Nausea, vomiting, and loss of appetite.
• Abdominal pain that can mimic peptic ulcer disease.

Psychiatric & cognitive symptoms

• Anxiety, irritability, or depression.
• Confusion, memory lapses, or difficulty concentrating.

Dermatologic manifestations

• Dry, coarse skin and brittle nails.
• Hair loss (alopecia) in long‑standing cases.

Bone health

• Osteomalacia or rickets in children – soft, weak bones leading to fractures.

Causes and Risk Factors

Hypocalcemia can be caused by many conditions; Klinenberg disease specifically refers to a hereditary, PTH‑related defect.

Genetic causes

• CASR gene mutations (Calcium‑Sensing Receptor) – lead to autosomal dominant hypocalcemia (ADH) with or without hypercalciuria. This is the most common molecular basis for Klinenberg disease.
• GCM2 gene mutations – affect parathyroid development and cause familial isolated hypoparathyroidism.
• GCMB (GATA3) mutations – part of Barakat syndrome, which can present with hypocalcemia.

Non‑genetic contributors that can precipitate or worsen the condition

• Vitamin D deficiency (low sunlight exposure, malabsorption, chronic kidney disease).
• Post‑surgical removal or damage to the parathyroid glands (e.g., thyroidectomy).
• Magnesium deficiency – impairs PTH secretion.
• Medications such as bisphosphonates, loop diuretics, or anticonvulsants (phenytoin, phenobarbital).
• Severe pancreatitis or massive blood transfusions (citrate binding calcium).

Risk groups

• Individuals with a first‑degree relative diagnosed with familial hypoparathyroidism.
• Patients who have undergone neck surgery.
• People with chronic kidney disease (CKD) stage 3‑5.
• Adults with limited sun exposure or malabsorption syndromes (celiac disease, Crohn’s).

Diagnosis

Diagnosing Klinenberg disease follows the standard work‑up for hypocalcemia, with additional genetic testing to confirm the hereditary form.

Initial laboratory evaluation

• Serum total calcium – measured after correcting for albumin; ionized calcium is preferred for accuracy.
• Parathyroid hormone (PTH) level – low or inappropriately normal in hypoparathyroidism.
• Serum phosphate – often elevated when PTH is low.
• 25‑hydroxyvitamin D – to rule out vitamin D deficiency.
• Serum magnesium – low magnesium can mimic or aggravate hypocalcemia.

Ancillary studies

• Electrocardiogram (ECG) – look for a prolonged QT interval.
• Renal ultrasound – assess for nephrocalcinosis in cases with hypercalciuria.
• Bone densitometry (DEXA) – evaluate for osteopenia/osteoporosis.

Genetic testing

When laboratory results suggest hypoparathyroidism without an obvious surgical cause, sequencing of the CASR, GCM2, and related genes is recommended. Commercial panels or whole‑exome sequencing are now widely available and can confirm a diagnosis of Klinenberg disease.

Diagnostic criteria (simplified)

1. Persistent serum calcium < 8.5 mg/dL (ionized < 1.12 mmol/L) on at least two separate occasions.
2. Inappropriately low or normal PTH level.
3. Exclusion of secondary causes (vitamin D deficiency, renal failure, medication).
4. Identification of a pathogenic variant in a gene known to cause familial hypoparathyroidism.

Treatment Options

Treatment aims to normalize calcium levels, relieve symptoms, and prevent long‑term complications while minimizing hypercalciuria (excess calcium in urine) that can damage kidneys.

Acute management

• Intravenous calcium gluconate (10 % solution) – 1‑2 mL/kg bolus over 10 minutes, followed by a continuous infusion if needed. This is used for severe tetany, seizures, or cardiac arrhythmias.
• Correction of magnesium deficiency (IV magnesium sulfate) before calcium replacement if Mg < 1.7 mg/dL.

Maintenance therapy

1. Oral calcium carbonate or calcium citrate – typical dose 1,000‑1,500 mg elemental calcium daily, divided in 2–3 doses.
2. Active vitamin D analogs – calcitriol (0.25‑0.5 µg BID) or alfacalcidol to enhance intestinal calcium absorption.
3. Thiazide diuretics (e.g., hydrochlorothiazide 12.5‑25 mg daily) – reduce urinary calcium excretion; useful in patients with hypercalciuria.
4. Recombinant human PTH (rhPTH 1‑84) – FDA‑approved for chronic hypoparathyroidism when conventional therapy fails or causes side effects. Dosing starts at 25 µg subcutaneously daily, titrated to maintain calcium within the low‑normal range.

Lifestyle & dietary measures

• Consume calcium‑rich foods (dairy, fortified plant milks, leafy greens).
• Ensure adequate vitamin D (sun exposure 10‑15 min daily, fortified foods, or supplements 800‑1,000 IU/day).
• Stay hydrated to reduce stone formation.
• Limit sodium and animal protein, which increase urinary calcium loss.

Monitoring

After initiating therapy, check serum calcium, phosphate, magnesium, and creatinine every 1–2 weeks initially, then every 3–6 months once stable. Periodic 24‑hour urinary calcium excretion helps detect hypercalciuria.

Living with Klinenberg disease (hypocalcemia)

Long‑term management is a partnership between the patient, endocrinologist, and primary‑care provider.

Daily habits

• Take calcium and vitamin D supplements with meals to improve absorption.
• Carry a medical alert bracelet that mentions “Hypocalcemia – may require calcium infusion.”
• Maintain a symptom diary (tingling, muscle cramps, mood changes) to discuss with your doctor.
• Schedule regular dental check‑ups—low calcium can affect tooth health.

Physical activity

• Weight‑bearing exercise (walking, resistance training) supports bone density.
• Avoid prolonged high‑intensity workouts that may precipitate tetany if calcium drops.

Travel tips

• Bring extra supply of oral calcium and vitamin D; keep them in original labeled containers.
• Stay hydrated, especially on long flights or in hot climates.
• Know the location of the nearest emergency department in case of severe symptoms.

Prevention

Because the hereditary form cannot be prevented, focus is on early detection and avoidance of secondary triggers.

• Family screening – first‑degree relatives should have serum calcium and PTH checked, and genetic counseling offered.
• Vitamin D sufficiency – maintain serum 25‑OH vitamin D >30 ng/mL.
• Magnesium balance – consume magnesium‑rich foods (nuts, seeds, whole grains) or supplement if needed.
• Medication review – discuss with your physician any drugs known to lower calcium (e.g., certain diuretics, bisphosphonates).

Complications

If left untreated or poorly managed, chronic hypocalcemia can lead to serious health issues.

• Neurological – recurrent seizures, basal ganglia calcifications, chronic paresthesia.
• Cardiac – prolonged QT interval, ventricular arrhythmias, sudden cardiac death.
• Renal – nephrolithiasis, nephrocalcinosis, chronic kidney disease from hypercalciuria.
• Skeletal – osteopenia/osteoporosis, increased fracture risk, rickets in children.
• Psychiatric – anxiety, depression, cognitive impairment.

When to Seek Emergency Care

References

1. Mayo Clinic. “Hypocalcemia.” Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health, Office of Dietary Supplements. “Calcium.” 2022. https://ods.od.nih.gov
3. NIH Genetic and Rare Diseases Information Center. “Hypoparathyroidism.” 2024. https://rarediseases.info.nih.gov
4. Cleveland Clinic. “Hypocalcemia Treatment.” 2023. https://my.clevelandclinic.org
5. WHO. “Guidelines for the Management of Calcium Disorders.” 2021. https://www.who.int

```